@lls8000
Hello Lisa:
The FDA has announced that the approval for Dato-Dxd use for in metastatic triple negative breast cancer or unresectable (cannot be surgically removed) triple negative breast cancer will be effective on May 2, 2026. That's great news and only a few weeks away.

Dato-Dxd is already approved for certain other breast cancers and for non small cell lung cancer (NSCLC).

This is fabulous news for mTNBC folks who have limited chemo/ADC options since we lack any hormone receptors. It's great to have another excellent ADC beyond sacituzumab govitecan.